158 related articles for article (PubMed ID: 27295577)
1. Clinical progress and pharmacology of small molecule bromodomain inhibitors.
Theodoulou NH; Tomkinson NC; Prinjha RK; Humphreys PG
Curr Opin Chem Biol; 2016 Aug; 33():58-66. PubMed ID: 27295577
[TBL] [Abstract][Full Text] [Related]
2. Progress in the Development of non-BET Bromodomain Chemical Probes.
Theodoulou NH; Tomkinson NC; Prinjha RK; Humphreys PG
ChemMedChem; 2016 Mar; 11(5):477-87. PubMed ID: 26749027
[TBL] [Abstract][Full Text] [Related]
3. Advancements in the Development of non-BET Bromodomain Chemical Probes.
Clegg MA; Tomkinson NCO; Prinjha RK; Humphreys PG
ChemMedChem; 2019 Feb; 14(4):362-385. PubMed ID: 30624862
[TBL] [Abstract][Full Text] [Related]
4. Fragment-Based Drug Discovery in the Bromodomain and Extra-Terminal Domain Family.
Radwan M; Serya R
Arch Pharm (Weinheim); 2017 Aug; 350(8):. PubMed ID: 28714212
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands.
Jennings LE; Measures AR; Wilson BG; Conway SJ
Future Med Chem; 2014 Feb; 6(2):179-204. PubMed ID: 24467243
[TBL] [Abstract][Full Text] [Related]
6. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
Theodoulou NH; Bamborough P; Bannister AJ; Becher I; Bit RA; Che KH; Chung CW; Dittmann A; Drewes G; Drewry DH; Gordon L; Grandi P; Leveridge M; Lindon M; Michon AM; Molnar J; Robson SC; Tomkinson NC; Kouzarides T; Prinjha RK; Humphreys PG
J Med Chem; 2016 Feb; 59(4):1425-39. PubMed ID: 25856009
[TBL] [Abstract][Full Text] [Related]
7. Bromodomains and their pharmacological inhibitors.
Gallenkamp D; Gelato KA; Haendler B; Weinmann H
ChemMedChem; 2014 Mar; 9(3):438-64. PubMed ID: 24497428
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors of bromodomain-acetyl-lysine interactions.
Brand M; Measures AR; Wilson BG; Cortopassi WA; Alexander R; Höss M; Hewings DS; Rooney TP; Paton RS; Conway SJ
ACS Chem Biol; 2015 Jan; 10(1):22-39. PubMed ID: 25549280
[TBL] [Abstract][Full Text] [Related]
9. Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors.
Bamborough P; Chung CW; Furze RC; Grandi P; Michon AM; Watson RJ; Mitchell DJ; Barnett H; Prinjha RK; Rau C; Sheppard RJ; Werner T; Demont EH
J Med Chem; 2018 Sep; 61(18):8321-8336. PubMed ID: 30226378
[TBL] [Abstract][Full Text] [Related]
10. Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology.
Galdeano C; Ciulli A
Future Med Chem; 2016 Sep; 8(13):1655-80. PubMed ID: 27193077
[TBL] [Abstract][Full Text] [Related]
11. Identification of Covalent Bromodomain Binders through DNA Display of Small Molecules.
Daguer JP; Zambaldo C; Abegg D; Barluenga S; Tallant C; Müller S; Adibekian A; Winssinger N
Angew Chem Int Ed Engl; 2015 May; 54(20):6057-61. PubMed ID: 25772490
[TBL] [Abstract][Full Text] [Related]
12. Research progress of selective small molecule bromodomain-containing protein 9 inhibitors.
Hui M; Jian Z; Peiyuan Z; Zhenwei W; Huibin Z
Future Med Chem; 2018 Apr; 10(8):895-906. PubMed ID: 29620420
[TBL] [Abstract][Full Text] [Related]
13. Bromodomains: pockets with therapeutic potential.
Papavassiliou KA; Papavassiliou AG
Trends Mol Med; 2014 Sep; 20(9):477-8. PubMed ID: 24986769
[TBL] [Abstract][Full Text] [Related]
14. Bromodomains: a new target class for drug development.
Cochran AG; Conery AR; Sims RJ
Nat Rev Drug Discov; 2019 Aug; 18(8):609-628. PubMed ID: 31273347
[TBL] [Abstract][Full Text] [Related]
15. BET inhibitors in cancer therapeutics: a patent review.
Ghoshal A; Yugandhar D; Srivastava AK
Expert Opin Ther Pat; 2016; 26(4):505-22. PubMed ID: 26924192
[TBL] [Abstract][Full Text] [Related]
16. Chemical probes and inhibitors of bromodomains outside the BET family.
Moustakim M; Clark PGK; Hay DA; Dixon DJ; Brennan PE
Medchemcomm; 2016 Dec; 7(12):2246-2264. PubMed ID: 29170712
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
18. Advances in discovering small molecules to probe protein function in a systems context.
Doyle SK; Pop MS; Evans HL; Koehler AN
Curr Opin Chem Biol; 2016 Feb; 30():28-36. PubMed ID: 26615565
[TBL] [Abstract][Full Text] [Related]
19. Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking.
Zhao H; Gartenmann L; Dong J; Spiliotopoulos D; Caflisch A
Bioorg Med Chem Lett; 2014 Jun; 24(11):2493-6. PubMed ID: 24767840
[TBL] [Abstract][Full Text] [Related]
20. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.
Qin C; Hu Y; Zhou B; Fernandez-Salas E; Yang CY; Liu L; McEachern D; Przybranowski S; Wang M; Stuckey J; Meagher J; Bai L; Chen Z; Lin M; Yang J; Ziazadeh DN; Xu F; Hu J; Xiang W; Huang L; Li S; Wen B; Sun D; Wang S
J Med Chem; 2018 Aug; 61(15):6685-6704. PubMed ID: 30019901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
